APFED’s Hypereosinophilic Syndromes Patient Education and Drug Development Conference was held March 23, 2018, in Rockville, MD. It offered a unique opportunity to learn about treatments and research advances for hypereosinophilic syndromes (HES), and to share perspectives with the FDA and other key stakeholders about the impact HES has had on on people with HES and their families, as well as learn about their views on current treatment approaches. Dynamic sessions and question and answer opportunities allowed all those who participated in-person and by live webcast to learn and share knowledge.
Thank you to our education partner Knopp Biosciences for supporting the conference.
Conference Materials
- Conference agenda (PDF)
- Speaker bios (PDF)
- HES patient guide (PDF)
- View the session recordings (YouTube playlist)
Patient Perspective Summary Report
Conference Transcripts
- Patient Perspectives on Impact of Disease on Daily Life
- Patient Perspectives on Current Therapies
- Patient Perspectives on Ideal Treatments
Conference Recordings
Conference Opening and Welcome Remarks
Dr. Wendy Book
APFED President
Patient-Centered Therapies: The Role of the Patient in Drug Development (Part 1)
Dr. Calman Prussin
Knopp Biosciences
Patient-Centered Therapies: The Role of the Patient in Drug Development (Part 2)
Dr. Dawn Phillips
Evidera
Hypereosinophilic Syndromes, Then and Now: Perspective Piece
Dr. Gerald Gleich
University of Utah
Patient Perspectives on Impact of Disease on Daily Life
Patient Panel
Patient Perspectives on Current Therapies
Patient Panel
Current Treatment Options and Side Effects
Dr. Paneez Khoury
National Institutes of Health
Patient Perspectives on Ideal Treatments
Patient Panel
Pediatric vs Adult HES
Dr. Patricia Fulkerson
Cincinnati Children’s Hospital Medical Center
Connecting with Resources and Support: For Patients and Providers
Mary Jo Strobel
APFED Executive Director